STADA Arzneimittel Aktiengesellschaft Financials

STADA Arzneimittel Stock Summary

STADA Arzneimittel competes with Hudson Technologies, Gulf Resources, Alto Ingredients, CF Industries, and Zhihu. STADA Arzneimittel Aktiengesellschaft engages in the health care and pharmaceuticals business worldwide. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare GmbH. Stada Arzneimi operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 123 people.

STADA Arzneimittel Key Financial Ratios

Generally speaking, STADA Arzneimittel's financial ratios allow both analysts and investors to convert raw data from STADA Arzneimittel's financial statements into concise, actionable information that can be used to evaluate the performance of STADA Arzneimittel over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that STADA Arzneimittel reports annually and quarterly.

STADA Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining STADA Arzneimittel's current stock value. Our valuation model uses many indicators to compare STADA Arzneimittel value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across STADA Arzneimittel competition to find correlations between indicators driving STADA Arzneimittel's intrinsic value. More Info.STADA Arzneimittel Aktiengesellschaft is currently regarded as top stock in return on equity category among related companies. It is currently regarded as top stock in return on asset category among related companies reporting about  0.28  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for STADA Arzneimittel Aktiengesellschaft is roughly  3.53 . Comparative valuation analysis is a catch-all model that can be used if you cannot value STADA Arzneimittel by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for STADA Arzneimittel's OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the STADA Arzneimittel's earnings, one of the primary drivers of an investment's value.

Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the STADA Arzneimittel information on this page should be used as a complementary analysis to other STADA Arzneimittel's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

If you are still planning to invest in STADA Arzneimittel check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the STADA Arzneimittel's history and understand the potential risks before investing.